Phase-III study of Avastin-Tarceva combo for lung cancer fails to meet primary endpoint
Wednesday, October 08, 2008 17:00 IST South San Francisco, California
Genentech, Inc and OSI Pharmaceuticals, Inc announced that a randomized phase-III study (BeTa Lung) evaluating Avastin (bevacizumab) in combination with Tarceva (erlotinib) in patients